Search results for "Antithrombotic"

showing 10 items of 66 documents

Is Aspirin a Worthy Candidate in Preventing Intracranial Aneurysm Rupture?

2020

Subarachnoid hemorrhage (SAH) usually occurs with a thunderclap headache or the worst headache of a patient's life, leading to a neurologic emergency. Among cases of nontraumatic SAH, 80%–85% are caused by ruptured intracranial aneurysms (IAs) and comprise 3% of all strokes in high-income countries In the years 2000–2008, the incidence of SAH was 4–7 per 100,000 person-years in high-income and low-to middle-income countries. Outcome after aneurysmal SAH depends on several factors, including severity of the initial hemorrhage, rebleeding, perioperative medical management, and timing and technical success for vascular malformation exclusion from the cerebral circulation. It has been estimated…

Intracranial bleedmedicine.medical_specialtySubarachnoid hemorrhageAneurysm RupturedAneurysm ruptureAneurysmAntithromboticFibrinolytic AgentsMedicineHumansAspirinFibrinolytic AgentAspirinbusiness.industrySurgical clippingIntracranial AneurysmSubarachnoid Hemorrhagemedicine.diseaseClopidogrelAneurysmSurgeryClopidogrelSurgeryNeurology (clinical)Intracranial bleedbusinessSurgical clippingFibrinolytic agentmedicine.drugHumanWorld neurosurgery
researchProduct

A new pro-thrombotic mechanism of neutrophil extracellular traps in antiphospholipid syndrome: impact on activated protein C resistance

2021

Abstract Objectives In APS, precise evaluation of thrombotic risk is a major challenge. Different players, such as activated protein C (APC) resistance or neutrophil extracellular traps (NETs) contribute to the risk of thrombosis. Nevertheless, no study has investigated the interaction between these actors. The main objective of this study was to investigate the relation between NETs and APC resistance. Methods We designed a cross-sectional study including APS/antiphospholipid antibodies (aPL) patients and patients with autoimmune diseases (AID). We performed thrombin generation tests without and with APC to determine APC resistance. To evaluate circulating NETs, we measured plasma levels o…

Lupus anticoagulantbiologybusiness.industryThrombosisNeutrophil extracellular trapsAntiphospholipid Syndromemedicine.diseaseExtracellular TrapsThrombosisCross-Sectional StudiesRheumatologyAntiphospholipid syndromeImmunologyAntithromboticmedicinebiology.proteinHumansPharmacology (medical)AntibodyActivated protein C resistancebusinessProtein CActivated Protein C Resistancemedicine.drugRheumatology
researchProduct

Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized C…

2020

Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvenci&oacute

Male0301 basic medicineVitamin KTime FactorsMediterranean diet030204 cardiovascular system & hematologyPharmacology4-HydroxycoumarinsDiet Mediterraneanchemistry.chemical_compound0302 clinical medicinepreventionAntithromboticNutsEnzyme InhibitorsDiet Fat-RestrictedUncategorizedNutrition and DieteticsMiddle AgedClopidogrelVitamines KCardiovascular Diseasesrandomized controlled trialsRandomized controlled trialsPlatelet aggregation inhibitorDietaFemaleVitamin K epoxide reductaselcsh:Nutrition. Foods and food supplymedicine.druglcsh:TX341-641Article03 medical and health sciencesMediterranean cookingFibrinolytic AgentsMediterranean dietVitamin K Epoxide ReductasesPlatelet aggregation inhibitorsCuina mediterràniamedicineHumansTiclopidineplatelet aggregation inhibitorsOlive OilAgedMediterranean DietMalalties cardiovascularsbusiness.industryPreventionWarfarinDiet4-hydroxycoumarins030104 developmental biologychemistryHeart Disease Risk FactorsbusinessFood Science
researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke: The GIFA Study

2004

Background and Purpose— Antithrombotic therapy has been demonstrated as an effective tool for secondary ischemic stroke prevention. Nevertheless, scant data are available on actual prescription of this therapy in clinical practice. Methods— A total of 17 337 patients admitted to geriatric and internal medicine wards participating in the study in the 1993 to 1998 survey period were analyzed. Patients with coded diagnoses of ischemic stroke and transient ischemic attack (TIA) were selected. Data recorded included demographic and clinical characteristics and medication prescription during hospital stay and at discharge. Logistic regression analyses were used to identify conditions associated …

MaleAgingmedicine.medical_specialtypharmacoepidemiologyEpidemiologymedicine.drug_classIschemiaMedication prescriptionNOBrain Ischemiastroke; prevention; aging; antithrombotic therapy; pharmacoepidemiologypreventionFibrinolytic AgentsEpidemiologyAntithromboticmedicineHumansMedical prescriptionStrokeAgedDemographyAntithrombotic therapyAdvanced and Specialized Nursingbusiness.industryAnticoagulantAnticoagulantsOdds ratiomedicine.diseaseHospitalizationStrokeIschemic Attack TransientAcute DiseaseEmergency medicinePhysical therapyFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsStroke
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct

Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre study

2020

International audience; Purpose To compare the risk of haemorrhagic complications in elective macular surgery between patients with no antithrombotic (AT) treatment (defined as patients with no history of AT therapy or who discontinued AT therapy) and patients who continued AT treatment during the surgery. Methods E-case report forms were prospectively recorded in a database before vitreoretinal surgery and 1 month after. Data on patient characteristics, surgical techniques, haemorrhagic complications and antithrombotic status were collected. Patients with retinal detachment, proliferative diabetic retinopathy and previous retinal haemorrhage were excluded. Results A total of 748 procedures…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologynoncardiac surgeryantiplateletsurgery0302 clinical medicineRisk FactorsAntithromboticMedicineProspective Studiesoral anticoagulantsguidelinesantithrombotic agenteducation.field_of_studyAnticoagulantvitreoretinalRetinal HemorrhageGeneral MedicineDiabetic retinopathy3. Good healthPopulation SurveillanceFemalemacular surgeryhaemorrhagehemorrhagemanagementmedicine.medical_specialtymedicine.drug_classPopulationPostoperative Hemorrhagemaintenance03 medical and health sciencesHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationAgedbusiness.industryanticoagulantAnticoagulantsPerioperativeOdds ratioRetinal Perforationsmedicine.diseasedual antiplatelet therapyvitreoretinal surgeryConfidence intervalSurgerywarfarinOphthalmology030221 ophthalmology & optometrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesRetinal haemorrhage
researchProduct

Management of bleeding in patients hospitalized in the intensive cardiac care unit: expert opinion of the Association of Intensive Cardiac Care and S…

2019

ABSTRACT Nowadays, the intensive cardiac care unit (ICCU) provides care for patients with acute coronary syndrome, acute and exacerbated chronic heart failure, cardiogenic shock, sudden cardiac arrest, electrical storm, as well as with indications for urgent cardiac surgical treatment. Most of these patients require the use of 1, 2, or frequently even 3 drugs that act on the blood coagulation pathway. While antithrombotic drugs prevent thromboembolic events, they are associated with a higher risk of bleeding. In this population of patients, bleeding may often have a worse impact on prognosis than the primary disease. In this expert opinion of the Association of Intensive Cardiac Care, we pr…

Malemedicine.medical_specialtyAcute coronary syndromePopulationCardiologyHemorrhagePharmacotherapyFibrinolytic AgentsRisk FactorsThromboembolismAntithromboticmedicineHumansIn patientCardiac Surgical ProceduresIntensive care medicineeducationSocieties MedicalAgedAged 80 and overeducation.field_of_studybusiness.industryCardiogenic shockDisease ManagementSudden cardiac arrestmedicine.diseaseIntensive Care UnitsHeart failureFemalePolandmedicine.symptomCardiology and Cardiovascular MedicinebusinessKardiologia polska
researchProduct

Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina

2006

SummaryApplication of clopidogrel before percutaneous coronary intervention in patients with acute coronary syndrome reduces the risk of cardiac events. Clopidogrel administration before surgery increases bleeding complications after CABG. Therefore, the antithrombotic effect of the low-dose combination of clopidogrel and aspirin was investigated in an in vivo pig model of coronary artery thrombus formation with cyclic flow reductions. The platelet inhibitory effect was determined by platelet aggregation and CFR, according to the methodology described by Folts. CFR were initiated by endothelial damage and placement of a constrictor around the LAD. 30 min after CFR were established, clopidog…

Malemedicine.medical_specialtyAcute coronary syndromeTiclopidinePlatelet AggregationSwinemedicine.medical_treatmentAnginaInternal medicineAntithromboticmedicineAnimalsPlateletAngina Unstablecardiovascular diseasesAspirinAspirinbusiness.industryUnstable anginaCoronary ThrombosisPercutaneous coronary interventionHematologymedicine.diseaseClopidogrelClopidogrelDisease Models AnimalAcute DiseaseCardiologyDrug Therapy CombinationbusinessPlatelet Aggregation Inhibitorscirculatory and respiratory physiologymedicine.drugThrombosis and Haemostasis
researchProduct

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct